Top Reddit Short Squeeze Mentions for Monday August 22, 2022: APRN, PRTY, BBBY, AMC, REV, GME, SNMP, BBIG, MNMD, DNAA
$AMC
$APRN
$BBBY
$BBIG
Movies/Entertainment
Consumer Discretionary
Catalog/Specialty Distribution
Consumer Discretionary
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 10/14/2024 | $20.00 | Outperform | Leerink Partners | |
| 7/24/2024 | $36.00 | Buy | ROTH MKM | |
| 5/29/2024 | $27.00 | Outperform | Robert W. Baird | |
| 4/15/2024 | $20.00 | Outperform | Leerink Partners | |
| 2/29/2024 | $12.00 → $8.00 | Neutral | B. Riley Securities | |
| 12/5/2023 | $9.00 | Buy | Canaccord Genuity | |
| 9/26/2023 | $15.50 → $4.75 | Sell | Citigroup | |
| 8/24/2023 | $19.00 | Underperform → Neutral | Wedbush |
Pitney Bowes Inc. (NYSE:PBI) ("Pitney Bowes" or the "Company"), a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to clients around the world, today announced the appointment of Lance Rosenzweig as the Company's permanent Chief Executive Officer ("CEO"), effective immediately. The Company's Board of Directors (the "Board") carried out an extensive CEO search process that was supported by a nationally recognized executive recruiting firm and included both internal and external candidates. After assessing Mr. Rosenzweig's considerable contributions as interim CEO and his track record of value creation at Pitney Bowes and at other co
ZURICH, Sept. 4, 2024 /PRNewswire/ -- Amcor (NYSE:AMCR, ASX: AMC))), a global leader in developing and producing responsible packaging solutions, today announced that its Board of Directors has appointed Peter Konieczny as Chief Executive Officer (CEO). Mr. Konieczny has served as Interim CEO since April 2024. The Board also intends to nominate him as a director for election at the Company's Annual Meeting of Shareholders which is expected to be held in November 2024. Amcor Chairman, Mr. Graeme Liebelt, said, "Peter has demonstrated exceptional leadership in every role he has
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next
Leerink Partners resumed coverage of MindMed with a rating of Outperform and set a new price target of $20.00
ROTH MKM initiated coverage of MindMed with a rating of Buy and set a new price target of $36.00
Robert W. Baird initiated coverage of MindMed with a rating of Outperform and set a new price target of $27.00
Wedbush analyst Alicia Reese reiterates AMC Enter Hldgs (NYSE:AMC) with a Neutral and maintains $4 price target.
Investors with a lot of money to spend have taken a bearish stance on GameStop (NYSE:GME). And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GME, it often means somebody knows something is about to happen. So how do we know what these investors just did? Today, Benzinga's options scanner spotted 21 uncommon options trades for GameStop. This isn't normal. The overall sentiment of these big-money traders is split between 4% bullish and 90%, bearish. Out of all of the special optio
Roth MKM analyst Jason Wittes maintains Mind Medicine (NASDAQ:MNMD) with a Buy and maintains $36 price target.
--On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024; 12-week topline data anticipated in the first half of 2026-- --On track to initiate the Phase 3 Panorama study of MM120 ODT in GAD and the Phase 3 Emerge study of MM120 ODT in Major Depressive Disorder (MDD) in the first half of 2025-- --Cash and cash equivalents of $295.3 million as of September 30, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD-- --Company to host a conference call today at 4:30 p.m. EST-- Mind Medicine (MindMed) Inc.
Exceeds guidance with revenue of $62.4 million Scatter revenue up 35% year-over-year National CineMedia, Inc. (NASDAQ:NCMI) ("the Company" or "NCM"), the managing member and owner of approximately 100% of National CineMedia, LLC (NCM LLC), the operator of the largest cinema advertising network reaching movie audiences in the U.S., today announced its consolidated results for the fiscal third quarter ended September 26, 2024. "NCM delivered its fourth consecutive quarter of consistent results, achieving $62.4 million in revenue, and demonstrating our strength as the box office continues to accelerate," said Tom Lesinski, CEO of NCM. "We continue to drive meaningful growth in our premium P
National CineMedia, Inc. (NASDAQ:NCMI) ("the Company" or "NCM"), the managing member of National CineMedia, LLC ("NCM LLC"), the operator of the largest cinema advertising platform in the U.S., plans to issue its third quarter 2024 earnings results after the market closes on Tuesday, November 5, 2024. A conference call and audio webcast to discuss the results will take place at 5:00 p.m. Eastern Time. The conference call can be accessed by dialing (844) 481-2522 or for international participants (412) 317-0550. Participants should register at least 15 minutes prior to the commencement of the call. Additionally, a live audio webcast will be available to interested parties at www.ncm.com und
AMC "goes on offense" with plans to expand its Premium Large Format ("PLF"), Extra Large Format ("XLF") and Laser at AMC footprint over the next four to seven years AMC's Go Plan also includes theatre renovations and seating upgrades at AMC theatres in the United States and ODEON Cinemas in Europe AMC's Go Plan positions AMC to thrive as the box office recovery gains momentum AMC Theatres® (NYSE:AMC), the largest theatrical exhibitor in the United States and in the world, today announced AMC's Go Plan, an ambitious investment in the future of moviegoing at AMC. Through AMC's Go Plan, AMC expects to invest between $1 billion and $1.5 billion over the next four to seven years, greatly enha
--On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024; 12-week topline data anticipated in the first half of 2026-- --On track to initiate the Phase 3 Panorama study of MM120 ODT in GAD and the Phase 3 Emerge study of MM120 ODT in Major Depressive Disorder (MDD) in the first half of 2025-- --Cash and cash equivalents of $295.3 million as of September 30, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD-- --Company to host a conference call today at 4:30 p.m. EST-- Mind Medicine (MindMed) Inc.
XL at AMC is the ultimate convenience for guests looking to see their movies on the biggest screens, with pristine 4K laser presentation Set to begin rolling out in the United States in early 2025, XL at AMC auditoriums will feature a screen at least 40 feet wide, 4K laser projection, a branded entry, and an online showtime designation, making the XL at AMC auditorium easy for guests to identify AMC is unveiling XL at AMC in 50 to 100 U.S. locations over the next year AMC Theatres® (NYSE:AMC), the largest theatrical exhibitor in the United States and in the world, today announced XL at AMC, a new "XLF" initiative that will make it easier than ever for guests to find the "extra-large" scr
SC 13G - AMC ENTERTAINMENT HOLDINGS, INC. (0001411579) (Subject)
SC 13G - AMC ENTERTAINMENT HOLDINGS, INC. (0001411579) (Subject)
SC 13G/A - AMC ENTERTAINMENT HOLDINGS, INC. (0001411579) (Subject)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - GameStop Corp. (0001326380) (Issuer)
10-Q - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
10-Q - AMC ENTERTAINMENT HOLDINGS, INC. (0001411579) (Filer)
4 - GameStop Corp. (0001326380) (Issuer)
4 - GameStop Corp. (0001326380) (Issuer)
4 - GameStop Corp. (0001326380) (Issuer)